We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Thrombus Perviousness as a Predictor of Differential Outcomes in Medium Vessel Occlusion Stroke: Tailoring IVT vs. EVT Strategies

MedXY Editorial Team•Aug 17, 2026•Neurology
Intravenous thrombolysisthrombus perviousnessmedium vessel occlusionstroke treatment outcomesEndovascular therapy

Highlight

  • Thrombus perviousness influences 90-day functional outcomes in acute medium vessel occlusion (MeVO) stroke.
  • Higher thrombus perviousness predicts better outcomes with intravenous thrombolysis (IVT), while lower perviousness favors endovascular therapy (EVT).
  • No significant differences were found in symptomatic intracranial hemorrhage or mortality rates across treatment modalities relative to thrombus perviousness.
  • Quantitative assessment of thrombus characteristics may guide personalized treatment strategies in MeVO stroke.

Study Background

Acute ischemic stroke caused by medium vessel occlusion (MeVO) represents a significant subset of cerebrovascular events with substantial morbidity and mortality. While intravenous thrombolysis (IVT) using tissue plasminogen activator remains a cornerstone therapy, the role of endovascular therapy (EVT) in MeVO is less clearly defined compared to large vessel occlusion strokes. Treatment benefits for IVT and EVT may vary not only by vessel size but also by thrombus composition and structure. Thrombus perviousness—a measure of how permeable a clot is to blood flow—has emerged as a potential imaging biomarker. By quantifying thrombus perviousness, clinicians can gain insights into clot characteristics that may influence responsiveness to thrombolytic therapy versus mechanical thrombectomy. Yet, the clinical implications of thrombus perviousness in guiding treatment choice for MeVO strokes are not well established.

Study Design

This investigation was a retrospective, single-center cohort study conducted at a leading stroke center in China, encompassing 255 consecutive patients diagnosed with imaging-confirmed medium vessel occlusion strokes treated between 2018 and 2024. Patients were treated either with IVT alone (n=154) or EVT with or without prior IVT (n=101). Thrombus perviousness was measured quantitatively using a thrombus perviousness index (TPI), derived from correlating noncontrast computed tomography (NCCT) and computed tomography angiography (CTA) images. The primary endpoint was functional independence at 90 days, defined as a modified Rankin Scale (mRS) score ≤2. Secondary analyses included safety endpoints such as symptomatic intracranial hemorrhage and mortality. Statistical evaluation employed multivariable logistic regression models and inverse probability of treatment weighting (IPTW) to control for confounding and assess the interaction between TPI and treatment modality.

Key Findings

Overall, 90-day functional independence rates were comparable between IVT and EVT groups (51.9% versus 51.5%; P=0.96), indicating similar aggregate efficacy. Importantly, TPI alone was not independently associated with functional outcome across the whole cohort. However, significant interaction effects between TPI and treatment modality emerged. In IPTW-weighted models, higher thrombus perviousness significantly increased the likelihood of functional independence among patients receiving IVT (odds ratio [OR] per 0.05-unit TPI increase, 1.73; 95% CI, 1.19–2.53; P=0.005). Conversely, in the EVT group, higher TPI was associated with a decreased probability of favorable outcome (OR, 0.65; 95% CI, 0.49–0.87; P=0.003). This suggests that thrombi that are more permeable are more amenable to IVT-induced recanalization, while less permeable thrombi might be better addressed mechanically. Exploratory analyses in the IVT subgroup revealed a continuous relationship between increasing TPI and improved outcomes without a clear threshold cutoff. Safety analyses showed no significant differences in rates of symptomatic intracranial hemorrhage or mortality when stratified by treatment or TPI.

Expert Commentary

Stroke experts recognize that thrombus composition, including fibrin density, red cell content, and calcification, may heavily influence treatment success. The concept of thrombus perviousness integrates these features into an imaging biomarker accessible via standard stroke imaging modalities. This study’s findings illuminate that perviousness can guide clinical judgment by identifying patients likely to benefit more from IVT or EVT in MeVO. While EVT has revolutionized treatment for large vessel occlusion, its generalizability in MeVO remains under evaluation, and indiscriminate use may not optimize patient outcomes. Notably, the lack of safety differences supports individualized decision-making based on imaging biomarkers rather than treatment modality alone.

Limitations include the retrospective single-center design and regional patient demographics, potentially limiting generalizability. Prospective validation and integration into clinical algorithms are warranted to confirm perviousness as a predictive tool. Additionally, mechanistic insights into why higher perviousness may reduce EVT efficacy require further investigation.

Conclusion

Thrombus perviousness is a promising imaging biomarker that modulates treatment outcomes in medium vessel occlusion stroke. Higher perviousness favors functional independence following intravenous thrombolysis, while lower perviousness suggests that mechanical thrombectomy may be more advantageous. These findings advocate for incorporating quantitative thrombus imaging assessments into acute stroke workflows to tailor revascularization strategies and potentially improve outcomes. Future prospective studies should validate TPI-guided personalized treatment algorithms and explore pathophysiological mechanisms linking thrombus characteristics to therapy responsiveness.

Funding and Clinical Trials Registration

This study was conducted at a stroke center in China with no specific external funding disclosed. The report did not specify registration with clinical trials databases.

References

1. Zhang M, Wu X, Qu Y, Zhang J, Jia W, Zhang Y, Wang S, Guo ZN, Jin H. Thrombus Perviousness Is Associated With Differential Treatment Outcomes Following IVT and EVT in MeVO Stroke. Stroke. 2026 Aug 17. PMID: 42605684.
2. Delgado Almandoz JE, Kayan Y, Rost NS, et al. Thrombus Permeability Is Associated With Improved Functional Outcome and Recanalization in Patients With Ischemic Stroke. Stroke. 2017;48(2):557-566.
3. Liebeskind DS, Sanossian N, Yong WH, et al. CT and MRI Early Vessel Signs Reflect Clot Composition in Acute Stroke. Stroke. 2011;42(5):1237-1243.
4. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.

(Additional literature on thrombus imaging and medium vessel occlusion treatment outcomes can be referenced as appropriate.)

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Baseline Ischemic Burden Influences Tenecteplase Benefit Before Thrombectomy in Acute Stroke: Insights from the BRIDGE-TNK TrialA post hoc analysis of the BRIDGE-TNK trial reveals that intravenous tenecteplase before endovascular thrombectomy significantly improves functional independence in acute large-vessel occlusion stroke patients with extensive baseline ischemAug 22, 2026Tailoring Blood Pressure Targets After Endovascular Therapy in Acute Ischemic Stroke: Clinical Trial InsightsA randomized trial shows reperfusion-guided blood pressure management post-thrombectomy improves functional outcomes and reduces hemorrhagic transformation, supporting personalized BP targets based on reperfusion status.Aug 11, 2026Perfusion Imaging’s Role in Endovascular Therapy Outcomes for Posterior Cerebral Artery StrokeThis study elucidates how baseline perfusion imaging parameters impact clinical outcomes and safety in isolated posterior cerebral artery occlusions treated with endovascular therapy, highlighting prognostic significance but limited predictJul 10, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Earlier IV Thrombolysis Before Thrombectomy Was Linked to Better In-Hospital Stroke Outcomes in RES-Q
A large multinational RES-Q registry analysis suggests that the benefit of bridging thrombolysis before thrombectomy is greatest when treatment starts very early, with attenuation after 150 minutes.
May 7, 2026
Atherectomy Fails to Improve Limb-Based Outcomes in Chronic Limb-Threatening Ischemia: A Critical Analysis of the BEST-CLI TrialA secondary analysis of the BEST-CLI trial indicates that atherectomy does not improve outcomes for patients with chronic limb-threatening ischemia undergoing endovascular therapy, with some data even suggesting potential harm in technicallJan 16, 2026
Emergent Carotid Stenting for Tandem Lesions Yields Superior One-Year Outcomes: Evidence from the SECURIS StudyThe SECURIS study demonstrates that emergent carotid artery stenting (eCAS) for tandem lesions in acute ischemic stroke significantly improves one-year functional outcomes and recanalization success without increasing hemorrhagic risks compJan 6, 2026